Randomized, Phase III Trial of Sequential Epirubicin and Docetaxel Versus Epirubicin Alone in Postmenopausal Patients With Node-Positive Breast Cancer

R. Charles Coombes*, Judith M. Bliss, Marc Espie, Frans L. G. Erdkamp, Jacob Wals, Alejandro Tres, Michel Marty, Robert E. Coleman, Nicole Tubiana-Mathieu, Marinus O. den Boer, Andrew Wardley, Lucy S. Kilburn, Derek Cooper, Marina W. K. Thomas, Justine A. Reise, Katie Wilkinson, Pierre Hupperets

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Fingerprint

Dive into the research topics of 'Randomized, Phase III Trial of Sequential Epirubicin and Docetaxel Versus Epirubicin Alone in Postmenopausal Patients With Node-Positive Breast Cancer'. Together they form a unique fingerprint.

INIS

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science